CLOV · Clover Health Investments, Corp. /De
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $40.3M | Three Months Ended March 31, 2026 | — |
| Adjusted Net income non-GAAP | $39.7M | Three Months Ended March 31, 2026 | — |
| Average Medicare Advantage membership | 154,607 | Three Months Ended March 31, 2026 | — |
|
|
|||
| Consolidated Gross profit non-GAAP | $159.5M | Three Months Ended March 31, 2026 | — |
| Insurance members | 155,773 | March 31, 2026 | +36.9% |
|
|
|||
| Adjusted SG&A non-GAAP | $334.2M | Full Year 2025 | — |
| Adjusted SG&A as a % of Total revenues non-GAAP | 17.4% | Full Year 2025 | — |
| Insurance BER non-GAAP | 90.9% | Full Year 2025 | — |
| Normalized Insurance BER non-GAAP | 91.5% | Full Year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Healthcare Plans — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLOV
this stock
Clover Health Investments, Corp. /De
|
$2.28B | +84.5% | +15.0% | — | 5.5% |
|
UNH
Unitedhealth Group Inc
|
$389.40B | +30.9% | +11.8% | 32.3 | 1.9% |
|
CVS
CVS HEALTH Corp
|
$139.51B | +38.9% | +10.9% | 48.0 | 1.5% |
|
ELV
Elevance Health, Inc.
|
$83.65B | +10.7% | +9.4% | 17.1 | 2.8% |
|
CI
Cigna Group
|
$79.64B | +10.0% | +11.2% | 12.8 | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLOV | -9.5% | -18.1% | +101.6% | -17.3% | +84.5% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -8.5% | -18.1% | +94.2% | -16.5% | +75.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.